Compare Gigacloud Technology Inc (GCT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Incyte Corporation — how do they compare? Gigacloud Technology Inc trades at $56.37 (market cap $2.02B), while Incyte Corporation trades at $113.19 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 11.3× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Incyte Corporation for 33 Days on average.
| GCT | INCY | |
|---|---|---|
Market Cap | $2.02B | $22.85B |
Volume | 1,020,985 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $56.42 | $129.93 |
52-Week Low | $25.46 | $83.80 |
Typical Hold Time | 21 Days | 33 Days |
Enterprise Value | $2.14B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $55.65, down 0.55% on the day, with a bullish technical outlook from moving averages and a consensus analyst rating of Buy. The stock shows strong fundamentals with a P/E of 13.44, net income margin of 10.65%, and consistent earnings beats in recent quarters. Revenue is projected to grow from $1.29B in 2025 to $1.5B in 2026, while operating cash flow remains robust at $190.66M.
The investment outlook is positive given valuation attractiveness and earnings momentum, but risks include insider selling and reliance on international expansion. Analyst price targets suggest potential upside to $32.50 consensus, though the current price exceeds this, indicating mixed signals. Key catalysts are EU market growth and continued execution against guidance.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
